This methodical approach reflects decades of clinical experience showing that slow titration improves long-term adherence and reduces treatment discontinuation due to side effects
SURMOUNT-5: The head-to-head trial Published in the New England Journal of Medicine in 2025, SURMOUNT-5 was the first randomised trial to directly compare tirzepatide (Mounjaro) with semaglutide (Wegovy) at equivalent maximum doses in adults with obesity without type 2 diabetes
Emerging Trends in Drugs, Addictions, and Health
The COA reports HPLC purity (99%), mass spectrometry identity confirmation, visual appearance, residual solvents, and moisture content for the exact lot shipped
Note: Cannabis is illegal at a federal level but is legal in many U.S
In this trial, tirzepatide at all three doses (5 mg, 10 mg, and 15 mg) achieved significantly greater weight loss compared to once weekly semaglutide 1 mg